VERRUGON Ointment (2014)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
1. Name of the medicinal product
Verrugon Ointment.
2. Qualitative and quantitative composition
Salicylic acid BP 50.00% w/w. <u>Excipients:</u> contains Wool fats 5.00% w/w. For a full list of excipients, see section 6.1.
3. Pharmaceutical form
Ointment. Off-white greasy ointment.
4.1. Therapeutic indications
For the treatment of verrucae (Plantar Warts).
4.2. Posology and method of administration
For Adults, Elderly and Children from 6 years onwards Fix the self adhesive ring with the hole over the verruca. Squeeze a little Verrugon ointment into the hole and directly on to the verruca. Cover ring ...
4.3. Contraindications
Not to be used by patients with diabetes or those with severe circulatory disorders or peripheral neuropathy except following a doctors permission or recommendation. Do not use if the verruca is already ...
4.4. Special warnings and precautions for use
Avoid contact with eyes or mucous membranes. If contact occurs flush with water for 15 minutes. Avoid contact with normal skin around the Verruca. Avoid using on areas of broken or damaged skin. Discontinue ...
4.5. Interaction with other medicinal products and other forms of interaction
There are no known interactions when used as indicated. However, salicylic acid may increase the absorption of other topically applied medicines. Concomitant use of Verrugon and other topical medicines ...
4.6. Fertility, pregnancy and lactation
Whilst there are no known contra-indications to the use of Verrugon during pregnancy and lactation, the safety has not been established. Verrugon should therefore be used with caution or following professional ...
4.7. Effects on ability to drive and use machines
Not applicable, none reported.
4.8. Undesirable effects
A localised irritant reaction may occur if Verrugon is applied to normal skin surrounding the Verruca. This may be controlled by temporarily discontinuing the use of Verrugon and by being careful to apply ...
4.9. Overdose
Symptoms of acute systemic salicylate poisoning have been reported after the application of salicylic acid to large areas of skin and for prolonged periods. Symptoms include dizziness, tinnitus, deafness, ...
5.1. Pharmacodynamic properties
Salicylic Acid is a bacteriostatic and fungicide. Used externally it has keratolytic properties and produces slow and painless destruction of verrucae, warts, corns and hard skin.
5.2. Pharmacokinetic properties
Salicylic acid may be percutaneously absorbed. However, there is no evidence of any systemic absorption from the use of Verrugon.
5.3. Preclinical safety data
No other information relevant to the prescriber other than that already stated in other sections of the SmPC.
6.1. List of excipients
White soft paraffin Glycerol Light liquid paraffin Wool fats (Lanesta S)
6.2. Incompatibilities
Not applicable.
6.3. Shelf life
5 years.
6.4. Special precautions for storage
Do not store above 25°C. Do not freeze.
6.5. Nature and contents of container
6g collapsible aluminium tube with emery board, 9 adhesive plasters and 9 corn rings.
6.6. Special precautions for disposal and other handling
No special requirements.
7. Marketing authorization holder
Optima Consumer Health Ltd, Concept House, Brackenbeck Road, Bradford BD7 2LW, UK
8. Marketing authorization number(s)
PA1904/002/001
9. Date of first authorization / renewal of the authorization
Date of first authorisation: 23 April 1992 Date of last renewal: 23 April 2007
10. Date of revision of the text
February 2014
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:
